Surgery and adjuvant dendritic cell-based tumor vaccination for patients with relapsed malignant glioma
Rutkowski, S De Vleeschouwer, S Kaempgen, E Wolff, JFA Soerensen, T Calenbergh, FA Van Gool, Stefaan
Carden Jennings Pub.
Neuro-Oncology vol:6 issue:4 pages:430-431
11th International Symposium on Pediatric Neuro-Oncology location:Boston: MA date:JUN 13-16, 2004
Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11-78) were treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of 5 (range: 2-7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12 patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden.